The company said it entered into an underwriting agreement on February 21, 2025 as guarantor with its wholly owned finance subsidiary, American Medical Systems Europe B.V. (issuer), and the underwriters. The underwriters agreed to buy €850,000,000 of 3.000% senior notes due 2031 and €650,000,000 of 3.250% senior notes due 2034.

1. 01

   The company said it entered into an underwriting agreement on February 21, 2025 as guarantor with its wholly owned finance subsidiary, American Medical Systems Europe B.V. (issuer), and the underwriters. The underwriters agreed to buy €850,000,000 of 3.000% senior notes due 2031 and €650,000,000 of 3.250% senior notes due 2034.

2. 02

   The company said AMS Europe completed the sale of the notes on February 26, 2025. It said net proceeds, after deducting the underwriting discount and estimated offering expenses payable by the company, were about €1.487 billion.

3. 03

   The company said it plans to use the net proceeds, together with cash on hand, to repay AMS Europe’s 0.750% senior notes due March 8, 2025 at maturity, pay accrued and unpaid interest on those notes, and for general corporate purposes.

4. 04

   The company said the notes are fully and unconditionally guaranteed by the company and were issued under an indenture dated March 8, 2022. It said the indenture contains covenants that restrict the ability to merge or consolidate or transfer all or substantially all assets, and to incur liens.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.